Esteban Olivera

Donanemab in Early Symptomatic Alzheimer Disease

John Randall Sims, Jennifer A. Zimmer, Cynthia Duggan Evans, Ming‐Chi Lu et autres

Importance: There are limited efficacious treatments for Alzheimer disease. Objective: To assess efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid plaque. Design, Setting, and Participants: Multicenter (277 medical research centers/hospitals in 8 countries), randomized, double-blind, placebo-controlled, 18-month …

us, se (code pays fourni par la source)

Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection

Cynthia Portal‐Celhay, Eduardo Forleo‐Neto, Will Eagan, Bret J. Musser et autres

Importance: The monoclonal antibody combination of casirivimab and imdevimab reduced viral load, hospitalization, or death when administered as a 1200-mg or greater intravenous (IV) dose in a phase 3 COVID-19 outpatient study. Subcutaneous (SC) and/or lower IV doses should increase accessibility and/or …

us (code pays fourni par la source)

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

Daniel K. Burns, Robert Alexander, Kathleen Anne Welsh-Bohmer, Meredith Culp et autres

ru, us (code pays fourni par la source)